These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14713926)

  • 81. Treatment of pneumonia with imipenem/cilastatin.
    Beasley CR; Humble MW; O'Donnell TV
    N Z Med J; 1985 Jun; 98(781):494-7. PubMed ID: 3859775
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus.
    Chandrasekar PH; Levine DP; Price S; Rybak MJ
    J Antimicrob Chemother; 1988 Apr; 21(4):461-9. PubMed ID: 3378959
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Rivera M; Crespo M; Teruel JL; Marcén R; Ortuño J
    Nephrol Dial Transplant; 1999 Jan; 14(1):258-9. PubMed ID: 10052540
    [No Abstract]   [Full Text] [Related]  

  • 84. Reversible encephalopathy with photoparoxysmal response during imipenem/cilastatin treatment.
    Gschwind M; Simonetta F; Vulliemoz S
    J Neurol Sci; 2016 Jan; 360():23-4. PubMed ID: 26723966
    [No Abstract]   [Full Text] [Related]  

  • 85. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
    McKinnon PS; Paladino JA; Grayson ML; Gibbons GW; Karchmer AW
    Clin Infect Dis; 1997 Jan; 24(1):57-63. PubMed ID: 8994756
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Imipenem/cilastatin-associated hiccups.
    Lucena M; Andrade R; Cabello M; Clavijo E; Queipo de Llano E
    Ann Pharmacother; 1992 Nov; 26(11):1459. PubMed ID: 1477457
    [No Abstract]   [Full Text] [Related]  

  • 87. In vitro effects of meropenem and imipenem/cilastatin on some functions of human natural effector cells.
    Cornacchione P; Scaringi L; Capodicasa E; Fettucciari K; Rosati E; Sabatini R; Benedetti C; Marconi P; Rossi R; Del Favero A
    Chemotherapy; 2000; 46(2):135-42. PubMed ID: 10671765
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Clinical evaluation of imipenem/cilastatin sodium in gynecological infection].
    Iwaki M; Sato H; Makinoda S; Demise M; Tabata M; Yamaguchi T; Takaoka H; Shinkai N; Okubo H; Sato H
    Jpn J Antibiot; 1986 Jun; 39(6):1509-13. PubMed ID: 3463791
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Imipenem/cilastatin.
    Lancet; 1988 Aug; 2(8607):376-7. PubMed ID: 2899781
    [No Abstract]   [Full Text] [Related]  

  • 90. Successful treatment of gram-negative bacillary meningitis with imipenem/cilastatin.
    Rodriguez K; Dickinson GM; Greenman RL
    South Med J; 1985 Jun; 78(6):731-2. PubMed ID: 3859018
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Seizure propensity with imipenem.
    Brown RB; Sands M; Morris AB
    Arch Intern Med; 1990 Jul; 150(7):1551. PubMed ID: 2369261
    [No Abstract]   [Full Text] [Related]  

  • 92. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 93. IgE-mediated anaphylactic reaction to imipenem.
    Chen Z; Baur X; Kutscha-Lissberg F; Merget R
    Allergy; 2000 Jan; 55(1):92-3. PubMed ID: 10696864
    [No Abstract]   [Full Text] [Related]  

  • 94. Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients.
    You X; Dai Q; Hu J; Yu M; Wang X; Weng B; Cheng L; Sun F
    J Glob Antimicrob Resist; 2024 Mar; 36():252-259. PubMed ID: 38272210
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Concerns Regarding ISPD Recommendations for Peritonitis in Relation to Imipenem/Cilastatin-In Reply.
    Szeto CC; Li PK
    Perit Dial Int; 2017; 37(5):585. PubMed ID: 28931702
    [No Abstract]   [Full Text] [Related]  

  • 96. First- and second-derivative spectrophotometric determination of imipenem and cilastatin in injections.
    Parra A; Garcia-Villanova J; Ródenas V; Gómez MD
    J Pharm Biomed Anal; 1993 Jun; 11(6):477-82. PubMed ID: 8399518
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safe use of imipenem after delayed hypersensitivity to meropenem-Value of patch tests.
    Morgado F; Santiago L; Gonçalo M
    Contact Dermatitis; 2020 Mar; 82(3):190-191. PubMed ID: 31742726
    [No Abstract]   [Full Text] [Related]  

  • 98. Determination of imipenem and cilastatin sodium in Primaxin by first order derivative ultraviolet spectrophotometry.
    Forsyth RJ; Ip DP
    J Pharm Biomed Anal; 1994 Oct; 12(10):1243-8. PubMed ID: 7841218
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Characteristics of Imipenem/Cilastatin: Considerations for Musculoskeletal Embolotherapy.
    Koucheki R; Dowling KI; Patel NR; Matsuura N; Mafeld S
    J Vasc Interv Radiol; 2021 Jul; 32(7):1040-1043.e1. PubMed ID: 34210475
    [No Abstract]   [Full Text] [Related]  

  • 100. Structure-activity relationships and drug allergy.
    Hasdenteufel F; Luyasu S; Hougardy N; Fisher M; Boisbrun M; Mertes PM; Kanny G
    Curr Clin Pharmacol; 2012 Feb; 7(1):15-27. PubMed ID: 22299766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.